YA-CHEN TINA SHIH to Health Expenditures
This is a "connection" page, showing publications YA-CHEN TINA SHIH has written about Health Expenditures.
Connection Strength
3.810
-
Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. JNCI Cancer Spectr. 2021 08; 5(4).
Score: 0.647
-
Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation. J Clin Oncol. 2020 02 01; 38(4):292-301.
Score: 0.586
-
Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care. Pharmacoeconomics. 2018 03; 36(3):259-261.
Score: 0.518
-
Prescription Drug Provisions in the Inflation Reduction Act: Any Relief of Financial Hardship for Patients With Cancer? JAMA Oncol. 2023 02 01; 9(2):165-167.
Score: 0.182
-
Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. J Natl Cancer Inst. 2022 10 06; 114(10):1392-1399.
Score: 0.178
-
Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer. JCO Oncol Pract. 2022 11; 18(11):e1739-e1749.
Score: 0.177
-
Cancer's Lasting Financial Burden: Evidence From a Longitudinal Assessment. J Natl Cancer Inst. 2022 07 11; 114(7):1020-1028.
Score: 0.175
-
Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening. J Natl Cancer Inst. 2022 02 07; 114(2):254-262.
Score: 0.170
-
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596.
Score: 0.161
-
Improving the Process of Screening for Medical Financial Hardship in Oncology Practice. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):593-596.
Score: 0.160
-
How much of US health care spending provides direct care or benefit to patients? Cancer. 2019 05 01; 125(9):1404-1409.
Score: 0.138
-
Impact on Oncology Practices of Including Drug Costs in Bundled Payments. J Oncol Pract. 2018 05; 14(5):e259-e268.
Score: 0.131
-
Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Cancer. 2018 01 15; 124(2):364-373.
Score: 0.126
-
Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications. J Oncol Pract. 2017 02; 13(2):e152-e162.
Score: 0.120
-
A flexible model for correlated medical costs, with application to medical expenditure panel survey data. Stat Med. 2016 Mar 15; 35(6):883-94.
Score: 0.109
-
Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. J Clin Oncol. 2015 Jul 01; 33(19):2190-6.
Score: 0.107
-
Economic burden of renal cell carcinoma in the US: Part II--an updated analysis. Pharmacoeconomics. 2011 Apr; 29(4):331-41.
Score: 0.080
-
Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. Cancer. 2022 07 01; 128(13):2455-2462.
Score: 0.043